СибНСХБ

Вид поиска

Область поиска

в найденном

Найдено в других БД

Формат представления найденных документов:
библиографическое описание	краткий	полный

Отсортировать найденные документы по:
автору	заглавию	году издания	типу документа

Поисковый запрос: (<.>S=ТЕРАПЕВТИЧЕСКИЙ ЭФФЕКТ<.>)

Общее количество найденных документов : 287
Показаны документы с 1 по 20

1-20 21-40 41-60 61-80 81-100 101-120

РЖ ВИНИТИ 76 (BI40) 95.01-04М7.287

Барановский, А. Ю.
Сравнительная терапевтическая эффективность маалокса у больных гастродуоденальной патологией [Текст] / А. Ю. Барановский, И. М. Журавская ; Тюм. мед. ин-т // Соврем. пробл. гастроэнтерол. - Курган, 1994. - С. 6-8 . - ISBN 5-87337-012-9

ГРНТИ	76.03.49

ВИНИТИ 761.03.49.39.33.17
Рубрики: ГАСТРИТ
ДУОДЕНИТ
БОЛЕЗНЬ ЯЗВЕННАЯ
МААЛОКС
ТЕРАПЕВТИЧЕСКИЙ ЭФФЕКТ
ЧЕЛОВЕК

Доп.точки доступа:
Журавская, И.М.

РЖ ВИНИТИ 34 (BI11) 95.04-04Б1.141

Vaccine therapy for ocular herpes simplex virus (HSV) infection: periocular vaccination reduces spontaneuos ocular HSV type 1 shedding in latently infected rabbits [Text] / A. B. Nesburn [et al.] // J. Virol. - 1994. - Vol. 68, N 8. - P5084-5092
Перевод заглавия: Вакцинотерапия инфекции глаз вирусом герпеса простого типа 1 (ВГП-1): периокулярная вакцинация угнетает спонтанное выделение от латентно инфицированных ВГП-1 кролков
Аннотация: Вводили латентно зараженным в глаза вирусом герпеса простого типа 1 (ВГП-1) кроликам в конъюнктиву периокулярно рекомбинантные гликопротеины В и D ВГП-2 (gB2 и gD2) с адъювантом, через 28 дней после заражения. Вакцину вводили трижды, с трехнедельным интервалом. У вакцинированных кроликов увеличивался в 5 раз титр нейтрализующих антител (по сравнению с получавшими плацебо). С помощью иммуноферментного анализа установили восьмикратное возрастание титра антител против gB2 и 60-кратное - против gD2. В 2,5 раза уменьшалось выделение вируса. Положительные рез-ты были подтверждены при статистическом анализе. Обсуждают возможность использования вакцины для лечения людей с рецидивирующим герпесом глаз. США, Ophthalmol. Res., Cedars-Sinai Med. Cent., Los Angeles, CA 90048. Библ. 38.

ГРНТИ	34.25.37

ВИНИТИ 341.25.37.09.31
Рубрики: ВИРУС ГЕРПЕСА ПРОСТОГО
ГЛИПОПРОТЕИНЫ
ИММУНОГЕННОСТЬ
ТЕРАПЕВТИЧЕСКИЙ ЭФФЕКТ
КРОЛИКИ
ГЛАЗНЫЕ ИНФЕКЦИИ

Доп.точки доступа:
Nesburn, A.B.; Burke, R.L.; Ghiasi, H.; Slanina, S.; Bahri, S.; Wechsler, S.L.

РЖ ВИНИТИ 76 (BI40) 95.05-04М7.168

Kyriakos, G.
Evaluation of FNAB findings and TSI-autibodies as prognostic factors in Grave's disease after treatment with thyonamide drugs [Text] / G. Kyriakos, M. Ioannidou // Acta Cytol. - 1994. - Vol. 38, N 4. - P641-642 . - ISSN 0001-5547
Перевод заглавия: Значение тонкоигловой биопсии и TSI-антител, как прогностического фактора и в оценке терапевтического эффекта тионамида при болезни Грейвса
Аннотация: Для прогноза и оценки результатов терапии тионамидом токсического зоба - болезни Грейвса использовали метод тонкоигловой биопсии и определения уровня TSIантител. Снижение последнего показателя до нормы как и нормализация цитологической картины были основанием к прекращению терапии. Греция, Ippokration Hosp., Athens.

ГРНТИ	76.03.49

ВИНИТИ 761.03.49.53
Рубрики: ГРЕЙВСА БОЛЕЗНЬ
АСПИРАЦИОННЫЕ БИОПСИИ
TSI-АНТИТЕЛА
ТИОНАМИД
ТЕРАПЕВТИЧЕСКИЙ ЭФФЕКТ
ЧЕЛОВЕК

Доп.точки доступа:
Ioannidou, M.

РЖ ВИНИТИ 76 (BI40) 95.06-04М7.230

Комплексный подход при лечении больных бронхиальной астмой [Текст] / В. Ю. Ким [и др.] ; Врач.-сан. служба Окт. ж. д. // Травмы груди и живота, сочетан. повреждения. Избр. вопр. гнойн. хирургии. - СПб, 1994. - С. 51-52
Аннотация: В течение последних 2 лет авт. при лечении бронхиальной астмы применяли комплекс методов лечения: оперативное лечение (гломэктомия, денервация корня легких, гемосорбция), УФ-облучение крови, глорефлексотерапия, электростимуляция дыхания. Изучены рез-ты лечения 18 больных в течение 6 мес. В 2 раза увеличился период ремиссии, уменьшилось число приступов в сутки, доза гормональных препаратов после лечения на 30-50% меньше чем до него.

ГРНТИ	76.03.49

ВИНИТИ 761.03.49.37.23.17
Рубрики: БРОНХИАЛЬНАЯ АСТМА
КОМПЛЕКСНОЕ ЛЕЧЕНИЕ
ТЕРАПЕВТИЧЕСКИЙ ЭФФЕКТ
ЧЕЛОВЕК

Доп.точки доступа:
Ким, В.Ю.; Карашуров, С.Е.; Ласков, В.Н.; Карашуров, Е.С.

РЖ ВИНИТИ 76 (BI31) 95.09-04Т3.44

Patient stage of change predicts outcome in a panic disorder medication trial [Text] / Bernard D. Beitman [et al.] // Anxiety. - 1994. - Vol. 1, N 2. - P64-69 . - ISSN 1070-9797
Перевод заглавия: Результат предвидения больным перемен при лечении панических расстройств
Аннотация: The authors test the hypothesis that patient readiness to change predicts outcome in a placebo-controlled medication trial. Method: Outpatients with panic disorder and agoraphobia completed the Stages of Change (SOC) questionnaire, a measure of readiness to change, before being randomly assigned either sustained release (SR) adinazolam or placebo in a 4 week double-blind trial. In the "intent to treat" analysis, for the 202 subjects who made at least one visit after baseline, adinazolam SR was significantly more effective than placebo on most major outcome measures. Of the 126 subjects who completed the SOC questionnaire, regression analyses showed significant correlations between SOC scores and all 5 outcome measures. In a second analysis, cluster membership based on SOC scores was predictive of outcome on 3 of 5 measures. In each atatistical analysis, subjects who were not predisposed to change as measured by the SOC were significantly less likely to change. Patient readiness to change was strongly correlated with outcome in a placebo-controlled panic disorder trial with an effective medication. In this study, the SOC category, Precontemplation (i. e., those subjects who reported the belief that they had no problem) were less likely to change compared to those who believed that they had a problem

ГРНТИ	76.31.29

ВИНИТИ 761.31.29.09.15.09
Рубрики: ПАНИЧЕСКИЕ РАССТРОЙСТВА
АГОРАФОБИЯ
ГОТОВНОСТЬ К ПЕРЕМЕНАМ
АНКЕТИРОВАНИЕ
АДИНАЗОЛАМ
ТЕРАПЕВТИЧЕСКИЙ ЭФФЕКТ
БОЛЬНЫЕ

Доп.точки доступа:
Beitman, Bernard D.; Beck, Niels C.; Deuser, William E.; Carter, Cameron S.; Davidson, Jonathan R.T.; Maddock, Richard J.

РЖ ВИНИТИ 76 (BI31) 95.09-04Т3.50

Use of phosphatidylserine in sporadic and familial Alzheimer's disease [Text] : abstr. 3rd Int. Conf. Alzheimer's Disease and Relat. Disorders, Abano Terme, July 12-17, 1992 / L. Bracco [et al.] // Neurobiol. Aging. - 1992. - Vol. 13, Suppl. n 1. - P123 . - ISSN 0197-4580
Перевод заглавия: Использование фосфатидилсерина при спорадической и наследственной болезни Алцгеймера
Аннотация: Evolution of the real activity of a drug requires numerous and extensive investigations. Obtaining valid results from clinical trials on dementia depends on two principal factors: the correct diagnosis of the disease underling the dementia syndrome, and the detection of specific cognitive and behavioral disturbance using neuropsychologic measures minimally influenced by different factors. Finally an important aspect of clinical trials on dementia, mainly AD, is the identification of specific outcomes of treatment and subgroups. In fact several factors such as age of onset, familiarity and specific neuropsychological features could effect the course of the disease. The results observed in our double-blind randomized placebo-controlled clinical trial suggest that oral intake of phosphatidylserine (PS) may improve performance on selected cognitive variables as well as prevent further cognitive deterioration in AD patients. Moreover we carried out clinical trials on AD patients taking into consideration the possibility that familial AD patients could respond to PS treatment in a different way respect to sporadic cases. We have also studied the effect of phosphatidylserine (PS) on oxygen metabolite toxicity in skin fibroblast cell lines from apparently normal subjects and from patients with familial and sporadic AD. Fibroblast damage was produced by the generation of oxygen metabolites during the enzymatic oxidation of acetaldehyde by xanthine-oxidase (X-O). In order to quantify cell damage, we measured lactate dehydrogenase (LDH) activity in culture medium and cell viability in fibroblast cultures, with and without preincubation with PS, after X-O incubation. We found a significant increase of LDH activity in cells without PS preincubation, providing evidence of the free radicals damage. No significant increase of LDH activity was observed in the same ce cell lines from normal subjects as well as from patients with familial and sporadic AD after preincubation with PS. In conclusion our study provided evidence suggesting that PS may protect normal and pathological fibroblasts, namely with familial and sporadic AD free radical damage and may be useful in the treatment of this disease

ГРНТИ	76.31.29

ВИНИТИ 761.31.29.09.21.11
Рубрики: АЛЦГЕЙМЕРА БОЛЕЗНЬ
СПОРАДИЧЕСКАЯ
НАСЛЕДСТВЕННАЯ
ФОСФАТИДИЛСЕРИН
МЕТАБОЛИЗМ КИСЛОРОДА
ЛАКТАТДЕГИДРОГЕНАЗА
ФИБРОБЛАСТЫ
ТЕРАПЕВТИЧЕСКИЙ ЭФФЕКТ
БОЛЬНЫЕ

Доп.точки доступа:
Bracco, L.; Falcini, M.; Piersanti, P.; Latorraca, S.; Piacentini, S.; Sorbi, S.; Amaducci, L.

РЖ ВИНИТИ 76 (BI31) 95.09-04Т3.52

Does chronic oral physostigmine alter the course of Alzheimer's disease? [Text] : abstr. 3rd Int. Conf. Alzheimer's Disease and Relat. Disorders, Abano Terme, July 12-17, 1992 / P. Storey [et al.] // Neurobiol. Aging. - 1992. - Vol. 13, Suppl. n 1. - P126 . - ISSN 0197-4580
Перевод заглавия: Длительный прием внутрь физостигмина изменяет ли течение болезни Алцгеймера?
Аннотация: There has been renewed interest in the use of cholinesterase inhibitors for the symptomatic treatment of Alzheimer's disease (AD). Although early studies questioned the effectiveness of this therapy, more recent investigations have demonstrated short-term benefit in some AD patients. Moreover, some studies have suggested long-term benefit in that disease progression has been reported to be slowed. These latter studies, however, suffer from small patient number (usually 10) and lack of controls. We sought to re-address this issue by investigating the effects of physostigmine on neuropsychological test performance in a larger number of AD patients and comparing this to a non-treated group of AD patients. Twenty-seven probable AD patients (NINCDS-ADRDA criteria) entering and outpatient trial of oral chronic physostigmine underwent dose finding, double-blind crossover, followed by chronic therapy with the highest tolerated dose (13.2 mg/day). Baseline and yearly neuropsychological assessment was performed with the following battery: Mattis Dementia Rating Scale; Intelligence (WAIS-subscale, Peabody Picture Vocabulary); Attention and Concentration (Wechsler Memory-R attention subscale, Trails A. B.); Language (Boston Naming, Controlled Oral Fluency); Perception (Benton Visual Form Discrimination, Tactile Form Recognition); Motor (Finger Tapping, Grooved Pegs); Memory (Wechsler Memory-R; Selective Reminding. Control probable AD (NINCDS-ADRDA) patients (n

ГРНТИ	76.31.29

ВИНИТИ 761.31.29.09.21.11
Рубрики: АЛЦГЕЙМЕРА БОЛЕЗНЬ
ФИЗОСТИГМИН
ДОЗЫ
ТЕРАПЕВТИЧЕСКИЙ ЭФФЕКТ
НЕЙРОФИЗИОЛОГИЧЕСКИЕ ПОКАЗАТЕЛИ
БОЛЬНЫЕ

Доп.точки доступа:
Storey, P.; Harrell, L.; Duke, L.; Callaway, R.; Marson, D.

РЖ ВИНИТИ 76 (BI31) 95.09-04Т3.54

Phosphatidylserine in the treatment of cognitive degline of elderly patients [Text] : abstr. 3rd Int. Conf. Alzheimer's Disease and Relat. Disorders, Abano Terme, July 12-17, 1992 / T. Bertoldin [et al.] // Neurobiol. Aging. - 1992. - Vol. 13, Suppl. n 1. - P126-127 . - ISSN 0197-4580
Перевод заглавия: Фосфатидилсерин при лечении снижения умственной деятельности при старческом слабоумии
Аннотация: Phosphatidylserine, a pharmacologically active phospholipid, has been shown to enhance the activities of membrane-bound enzymes involved in neurotransmitter release and signal transduction in the CNS. Clinical trials with phosphatidylserine have reported positive effects on the cognitive impairment and behavioral disturbances in elderly patients with mild to severe cognitive decline due to various etiologies, including Alzheimer's diseases. However, these trials have usually dealt with small groups of patients selected for the presumptive presence of senile dementias. In this double-blind study the therapeutic effects and the safety of orally treatment with phosphatidylserine vs placebo (300 mg/die for 6 months) was asseassed in a group of geriatric patients with cognitive impairment. A total of 494 elderly patients (age between 65 and 93 yrs), affected by moderate to severe cognitive decline according to the Mini Mental State Examination and Global Deterioration Scale, were recruited in 23 Geriatric or General Medicine Units is Northeastern Italy. Patients were examined just before starting the therapy, and 3 and 6 months thereafter. The efficacy of treatment compared with placebo was measured on the basis of changes occurring in behavior and cognitive performance using the Plutchik Geriatric Rating Scale and the Buschke Selective Reminding Test. Statistically significant improvements in the phosphatidylserine-treated group compared with placebo were observed both in terms of behavioral and cognitive parameters. Clinical evaluation and laboratory tests demonstrated that phosphatydilserine was well tolerated. These results are particular relevance in the light of the large number of patients enrolled in this study, who represent a sample of the geriatric population commonly encountered in clinical practice

ГРНТИ	76.31.29

ВИНИТИ 761.31.29.09.21.11
Рубрики: АЛЦГЕЙМЕРА БОЛЕЗНЬ
ФОСФАТИДИЛСЕРИН
ДОЗЫ
ПРОДОЛЖИТЕЛЬНОСТЬ ЛЕЧЕНИЯ
ТЕРАПЕВТИЧЕСКИЙ ЭФФЕКТ
БОЛЬНЫЕ ПОЖИЛЫЕ

Доп.точки доступа:
Bertoldin, T.; Farina, C.; Genacchi, T.; Grepaldi, G.

РЖ ВИНИТИ 76 (BI31) 95.09-04Т3.56

The effects of alpha-glycerylphosphorylcholine administration on the GH secretion of elderly subjects and of patients affected by senile dementia of the Alzheimer type [Text] : abstr. 3rd Int. Conf. Alzheimer's Disease and Relat. Disorders, Abano Terme, July 12-17, 1992 / G. P. Ceda [et al.] // Neurobiol. Aging. - 1992. - Vol. 13, Suppl. n 1. - P126 . - ISSN 0197-4580
Перевод заглавия: Эффекты применения альфа-глицерилфосфорилхолина на секрецию гормона роста у пожилых людей и больных старческим слабоумием по алцеймеровскому типу
Аннотация: GH secretion is blunted during aging in rodents and humans. Central cholinergic stimuli increase the secretion of GH from the pituitary; drugs like the cholinesterase inhibitor pyridostigmine induce GH release, potentiate the stimulatory effect of GHRH and restore the GH response after intermittent GHRH administration. These actions may be mediated by a decrease of somatostatin release. Since brain acetylcholine (Ach) synthesis declines with aging and in dementia, it may be possible to restore normal GH secretion by enhancing cholinergic tone. The putative Ach precursor, alphaglycerylphosphorylcholine (alpha-GFC), has been used for the treatment of amnestic and cognitive disorders of aging. In order to learn what effect alpha-GFC had on GH secretion, GHRH was given to young and old human volunteers and to a group of patients affected by SDAT. 8 young (aged 32'+-'1.9), 7 old subjects (aged 80'+-'2 y) and 5 patients affected by SDAT (aged 79'+-'2.1 y) were studied on separate days with 1) a bolus injection of 50 'мю'g GHRH (Geref, Serono) with blood samples taken at - 15 and O min and at 15, 30, 45, 60 and 90 min after the injection, and 2) a 30 min infusion of alpha-GFC (Brezal, Sandoz) (1g in 100 ml saline) followed by a GHRH bolus injection and samples obtained at the same times. The results showed that GH responses to GHRH were greater in the younger than in the older subjects and both groups had a greater GH response to the GHRH+alpha-GFC stimulation than to GHRH alone. However the potentiating effect of alpha-GFC was more pronounced in the elderly subjects. In patients affected by SDAT both GHRH and GHRH+alpha-GFC induced GH responses similar to that observed in the elderly normal subjects. These findings confirm the observation that 1) aged individuals respond less well to GHRH than younger subjects. 20 the pituitary responsiveness to GHRH in patients affected by SDAT is similar to that of normal subjects of comparable age, and document that 3) the enhancing effects of alpha-GFC is greater in normal elderly subjects. These results provide further evidence that increased cholinergic tone enhances GH release

ГРНТИ	76.31.29

ВИНИТИ 761.31.29.09.21.11
Рубрики: АЛЦГЕЙМЕРА БОЛЕЗНЬ
ГЛИЦЕРИЛФОСФОРИЛКОЛИН *АЛЬФА-
ТЕРАПЕВТИЧЕСКИЙ ЭФФЕКТ
СРАВНИТЕЛЬНЫЙ АНАЛИЗ
ЗДОРОВЫЕ МОЛОДЫЕ
ЗДОРОВЫЕ ПОЖИЛЫЕ
БОЛЬНЫЕ ПОЖИЛЫЕ

Доп.точки доступа:
Ceda, G.P.; Marzani, G.P.; Piovani, E.; Denti, L.; Banchini, A.; Tarditi, E.; Baggi, F.; Marchini, L.; Valenti, G.

10.

РЖ ВИНИТИ 76 (BI31) 95.09-04Т3.127

Local urokinase thrombolytic treatment in deep vein thrombosis (DVT) [Text] : abstr. and Invit. Lect. 12th Int. Congr. Fibrinolys., Leuven, Sept. 18-22, 1994 / F. Baudo [et al.] // Fibrinolysis. - 1994. - Vol. 8, Suppl. n 1. - P72 . - ISSN 0268-9499
Перевод заглавия: Местное тромболитическое лечение урокиназой тромбоза глубоких вен

ГРНТИ	76.31.29

ВИНИТИ 761.31.29.11.41.09
Рубрики: ТРОМБОЗЫ
ГЛУБОКИЕ ВЕНЫ
ФАКТОРЫ РИСКА
УРОКИНАЗА
ГЕПАРИН
ВАРФАРИН
ДОЗЫ
СПОСОБ И МЕСТО ВВЕДЕНИЯ
ПРОДОЛЖИТЕЛЬНОСТЬ ПРИМЕНЕНИЯ
ТЕРАПЕВТИЧЕСКИЙ ЭФФЕКТ
БОЛЬНЫЕ

Доп.точки доступа:
Baudo, F.; Cataldo, F.de; Caimi, T.M.; Russo, A.; Brambilla, G.; Rampoldi, A.

11.

РЖ ВИНИТИ 76 (BI31) 95.09-04Т3.161

Enzyme replacement treatment in type 1 and type 3 Gaucher's disease [Text] / B. Bembi [et al.] // Lancet. - 1994. - N 8938. - P1679-1682 . - ISSN 0140-6736
Перевод заглавия: Заместительная терапия ферментами при болезни Гоша (тип 1 и 3)
Аннотация: The development of intravenous enzyme-replacement treatment for Gaucher's disease has changed life expectancy in cases without neurological involvement (type 1). The effects in patients with neurological involvement are unknown. We treated 12 Italian patients, types 1 (9) and 3 (3), with intravenous alglucerase: 70-120 IU/kg per month for type 3 and 30-60 IU/kg per month for type 1. Maintenance infusions were biweekly in patients without neurological symptoms, whereas in one symptomatic type 3 patient, influsion was weekly. All patients improved; a resumption of growth in children with growth retardation was observed and spleen and liver reduced in size. In one type 3 patient, a bone callus formed during treatment and enabled the patient to walk. Laboratory tests showed rapid increase of haemoglobin in anaemic patients, and a slower response in patients with thrombocytopaenia. In 4 patients there was temporary hypocalcaemia immediately after the beginning of treatment. Neurological symptoms were present in 1 of the type 3 patients, and electroencephalogram was abnormal in another. After 2 years of treatment, the patient with symptoms showed an improvement of psychomotor skills and of IQ from 50 to 60. Genotype analysis showed a high frequency of the 1448C mutation (54*5%). The 9 patients carrying this allele came from Italian regions which in the past had been invaded from north Europe and Scandinavia. Enzyme replacement in Gaucher's type 1 can also be effective at low doses and even with a 2-week interval between infusions. This makes treatment cheaper, and reduces hospital stay for patients

ГРНТИ	76.31.29

ВИНИТИ 761.31.29.19.23.09
Рубрики: ГОША БОЛЕЗНЬ
ТИПЫ БОЛЕЗНИ
АЛГЛУЦЕРАЗА
ВНУТРИВЕННОЕ ВВЕДЕНИЕ
ДОЗЫ
ТЕРАПЕВТИЧЕСКИЙ ЭФФЕКТ
БОЛЬНЫЕ

Доп.точки доступа:
Bembi, B.; Zanatta, M.; Carrozzi, M.; Baralle, F.; Gornati, R.; Berra, B.; Agosti, E.

12.

РЖ ВИНИТИ 76 (BI31) 95.09-04Т3.222

Ganciclovir implant for cytomeg-alovirus retinitis treatment [Text] : abstr. Annu. Meet. Amer. Acad. Optometry, Boston, Mass., Dec. 9-14, 1993 / Ann E. Griepp [et al.] // Optometry and Vision Sci. - 1993. - Vol. 70, N 12 Suppl. - P60-61 . - ISSN 1040-5488
Перевод заглавия: Имплантация ганцикловира для лечения цитомегаловирусного ретинита
Аннотация: The most common ocular infection in patients with HIV disease in cytomegalovirus (CMV) retinitis. Typically, CMV-retinitis is treated using intravenous (IV) medications: foscarnet and ganciclovir. These IV medications cause numerous systemic toxicities, including: bone marrow suppression, renal toxicities, and nausea. Patients receiving these medications to catheter-related infections, often have an indwelling central line, which frequently leads to catheter-related infections, sepsis, and thrombosis. IV therapy is often interrupted due to these complications allowing for progression of CMV disease. In an attempt to treat patient's intolerant of IV therapy, we investigated an alternative local therapy for CMV retinitis, the ganciclovir implant. Twenty patients (n=20) participated in an FDA Phase II open-label study. All patients demonstrated regression of the CMV retinitis. Post-implantation two patients (10%) developed retinal detachments and four patients (20%) a self-limiting vitreitis. We demonstrated the effectiveness of the ganciclovir implant as a treatment for CMV retinitis

ГРНТИ	76.31.29

ВИНИТИ 761.31.29.39.11
Рубрики: ВИЧ-ИНФЕКЦИЯ
РЕТИНИТЫ
ЦИТОМЕГАЛОВИРУСНЫЕ
ФОСКАРНЕТ
ГАНЦИКЛОВИР
ИМПЛАНТАЦИЯ
ПОБОЧНЫЕ ЭФФЕКТЫ
ОСЛОЖНЕНИЯ
ТЕРАПЕВТИЧЕСКИЙ ЭФФЕКТ
БОЛЬНЫЕ

Доп.точки доступа:
Griepp, Ann E.; Smith, Duane D.; Chute, Richard R.; Robinson, Michael R.

13.

РЖ ВИНИТИ 76 (BI31) 95.09-04Т3.227

High-performance liquid chromatographic assay of plasma thalidomide: Stabilization of specimens and determination of a tentative therapeutic range for chronic graft-versus-host disease [Text] / B. J. Boughton [et al.] // Ann. Clin. Biochem. - 1995. - Vol. 32, N 1. - P79-83 . - ISSN 0004-5632
Перевод заглавия: Высокоэффективный жидкостной хроматографический метод определения содержания талидомида: стабилизация образцов и определение экспериментальных терапевтических границ у больных болезнью трансплантат против хозяина
Аннотация: Thalidomide is now widely used to treat chronic graft-versus-host disease, but its use is associated with non-teratogenic side effects such as peripheral neuropathy. To examine the value of monitoring plasma concentrations of the drug in such patients, we have developed a high-performance liquid chromatographic (HPLC) assay. The method uses 0*5 mL plasma, is linear to 10 mg/L and had a detection limit of 0*2 mg/L. Thalidomide in plasma specimens was unstable at physiological pH but could be stabilized for several weeks by simple acidification. We describe a protocol for monitoring patienst treated with thalidomide which permits convenient transportation and storage of specimens and report, provisionally, that plasma concentrations in the range 1-7 mg/L are therapeutically effective in chronic graft-versus-host disease without adverse side effects

ГРНТИ	76.31.29

ВИНИТИ 761.31.29.41.07
Рубрики: ТРАНСПЛАНТАЦИЯ
ТРАНСПЛАНТАТ ПРОТИВ ХОЗЯИНА
ХРОНИЧЕСКОЕ ТЕЧЕНИЕ
ТАЛИДОМИД
ВЭЖХ
СТАБИЛИЗАЦИЯ ОБРАЗЦОВ
СОДЕРЖАНИЕ В ПЛАЗМЕ
ТЕРАПЕВТИЧЕСКИЙ ЭФФЕКТ
ПОБОЧНЫЕ ЭФФЕКТЫ
БОЛЬНЫЕ

Доп.точки доступа:
Boughton, B.J.; Sheehan, T.M.T.; Wood, J.; O'Brien, D.; Butler, M.; Simpson, A.; Hale, K.A.

14.

РЖ ВИНИТИ 76 (BI31) 95.09-04Т3.230

Intraoperative administration of rt-PA during a case of digital revascularization [Text] : abstr. and Invit. Lect. 12th Int. Congr. Fibrinolys., Leuven, Sept. 18-22, 1994 / J. M. Stassen [et al.] // Fibrinolysis. - 1994. - Vol. 8, Suppl. n 1. - P71 . - ISSN 0268-9499
Перевод заглавия: Применение rt-PA во время операции по поводу реваскулиризации пальцев
Аннотация: Following a power-saw injury to his right hand, a 27-year old man was admitted for emergency reconstruction. The 2nd, 3rd and 4th fingers were devascularised, and all dorsal and deep palmar structures including bone, were divided at the metacarpal necks. The palmar skin and the corresponding superficial venous network were in continuity. Prior to surgery, the patient received aspirin 250 mg PO and a total of 500 ml dextran 70. The microvascular repair was performed through the dorsal wound. An interpositional venous graft from the dorsum of the patient's left foot was interpositioned into the common digital artery of the 2nd and third fingers. A transient hyperemia was observed in all three fingers immediately upon removal of the vascular clamps, but a state of no reflow incurred within 5 minutes. A more extensive palmar dissection, which would have been necessary to allow further arterial resection and reconstruction, was considered a hazard to the existing palmar venous outflow. Intraoperative thrombolytic therapy was therefore started with intraarterial infusion of rt-PA 800 'мю'g/h through the radial artery, after a 400 'мю'g bolus. Signs of reperfusion were first observed 1.5 hrs after initiation of the infusion, which was then decreased to 400 'мю'g/h during 2 hrs, and finally to 200 'мю'g/h during 1 hr. A significant bleeding from the wound area necessitated the transfusion of two units of blood. Postoperatively, the restoration of the blood flow was confirmed using finger pulp temperature measurements and transcutaneous laser doppler flowmetry. Intraoperative thrombolytic therapy was successfully used to restore digital blood flow in a case of arterial reconstruction with sign of arterial thrombosis

ГРНТИ	76.31.29

ВИНИТИ 761.31.29.41.09
Рубрики: ХИРУРГИЧЕСКИЕ ОПЕРАЦИИ
РЕВАСКУЛИРИЗАЦИЯ ПАЛЬЦЕВ
АСПИРИН
ДЕКСТРАН
RT-PA
ВНУТРИАРТЕРИАЛЬНАЯ ИНФУЗИЯ
ДОЗЫ
ТЕРАПЕВТИЧЕСКИЙ ЭФФЕКТ
БОЛЬНЫЕ

Доп.точки доступа:
Stassen, J.M.; Gang, L.; Andreen, O.; Nystrom, E.; Nystrom, A.

15.

РЖ ВИНИТИ 34 (BI23) 95.10-04М2.139

Local urokinase thrombolytic treatment in deep vein thrombosis (DVT) [Text] : abstr. and Invit. Lect. 12th Int. Congr. Fibrinolys., Leuven, Sept. 18-22, 1994 / F. Baudo [et al.] // Fibrinolysis. - 1994. - Vol. 8, Suppl. n 1. - P72 . - ISSN 0268-9499
Перевод заглавия: Местное тромболитическое лечение урокиназой тромбоза глубоких вен

ГРНТИ	34.39.27

ВИНИТИ 341.39.27.07.37.33
Рубрики: ТРОМБОЗЫ
ГЛУБОКИЕ ВЕНЫ
ФАКТОРЫ РИСКА
УРОКИНАЗА
ГЕПАРИН
ВАРФАРИН
ДОЗЫ
СПОСОБ И МЕСТО ВВЕДЕНИЯ
ПРОДОЛЖИТЕЛЬНОСТЬ ПРИМЕНЕНИЯ
ТЕРАПЕВТИЧЕСКИЙ ЭФФЕКТ
БОЛЬНЫЕ

Доп.точки доступа:
Baudo, F.; Cataldo, F.de; Caimi, T.M.; Russo, A.; Brambilla, G.; Rampoldi, A.

16.

РЖ ВИНИТИ 76 (BI31) 95.10-04Т3.65

A fixed-dose study of adinazolam-SR tablets in generalized anxiety disorder [Text] / Charles S. Wilcox [et al.] // Progr. Neuro-Psychopharmacol. and Biol. Psychiat. - 1994. - Vol. 18, N 6. - P979-993 . - ISSN 0278-5846
Перевод заглавия: Изучение фиксированных доз адиназолама-SR в таблетках при распространенном состоянии тревоги у больных
Аннотация: This four-week, randomized, double-blind, multicenter study compared the efficacy and safety of adinazolam-SR, at three dosage levels, with placebo. Forty (40) patients were randomized at our site: 10 to adinazolam 30 mg/day, 10 to 60 mg/day, 10 to 90 mg/day, and 10 to placebo. All patients were moderately anxious with Hamilton Anxiety Scale (HAM-A) scores of '='21 at baseline. The data were and analyzed by pooling the three adinazolam groups and comparing them with the placebo group using t-tests. HAM-A scores decreased significantly more in the pooled adinazolam-SR treatment group than in the placebo group at both Week one (p02) and at Week two, as well as at endpoint. At endpoint the adinazolam-treated group included 8 "responders" ('=' 50% reduction on the baseline HAM-A score) while none of the placebo patients were responders. Dose-response effects were evaluated and relationships were not statistically significant. The results indicate that adinazolam-SR was clearly superior to placebo for the treatment of patients suffering from Generalized Anxiety Disorder

ГРНТИ	76.31.29

ВИНИТИ 761.31.29.09.09
Рубрики: ТРЕВОГА
АДИНАЗОЛАМ-SR
ТАБЛЕТКИ
ДОЗЫ
ДОЗА-ОТВЕТ
ТЕРАПЕВТИЧЕСКИЙ ЭФФЕКТ
БОЛЬНЫЕ

Доп.точки доступа:
Wilcox, Charles S.; Ryan, Patrick J.; Morrissey, Judy L.; Cohn, Jay B.; Defrancisco, Don F.; Linden, Robert D.; Heiser, Jon F.

17.

РЖ ВИНИТИ 76 (BI31) 95.10-04Т3.98

The ESPRIM trial: Short-term treatment of acute myocardial infarction with molsidomine [Text] // Lancet. - 1994. - N 8915. - P91-97 . - ISSN 0140-6736
Перевод заглавия: Esprim исследование: краткосрочное лечение острого инфаркта миокарда молсидомином
Аннотация: Previous small clinical trials have suggested that treatment with nitric oxide donors in suspected myocardial infarction can reduce mortality by 30-35%. To confirm this finding in a large-scale trial, we compared molsidomine and its active metabolite linsidomine (a nitric oxide donor) with placebo in 4017 patients with acute myocardial infarction. In our trial, patients without signs of overt heart failure (Killip III/IV) were randomly assigned in a double-blind design within 24 h of symptom onset to receive linsidomine 1 mg/h intravenously for 48 h, followed by 16 mg molsidomine by mouth daily for 12 days (n=2007), or an identical placebo (n=2010). All other treatments could be used at the responsible physician's discretion with the exception of systematic vasodilator treatment. The molsidomine and placebo groups showed similar all-cause 35-day mortality (168 [8*4%] vs 176 [8*8%] deaths, p=0*66), and adjustment for baseline variables in a Cox model had no effect. Similarly, we found no difference for long-term mortality (mean follow-up 13 months; 294 [14*7%] vs 285 [14*2%] deaths, p=0*67). The two groups showed similar frequencies of major and minor adverse events; only headache was significantly more common in the molsidomine group. Changes in treatment practiced and the lower risk profile of our study subjects than of participants in previous trials may explain the results. It is still not clear whether nitric oxide donors can improve survival in higher-risk myocardial infarction patients

ГРНТИ	76.31.29

ВИНИТИ 761.31.29.11.11.11
Рубрики: ИНФАРКТ МИОКАРДА
ОСТРЫЙ
МОЛСИДОМИН
ЛИНСИДОМИН
ДОЗЫ
ПРОДОЛЖИТЕЛЬНОСТЬ ЛЕЧЕНИЯ
ТЕРАПЕВТИЧЕСКИЙ ЭФФЕКТ
БОЛЬНЫЕ

18.

РЖ ВИНИТИ 76 (BI31) 95.10-04Т3.99

Plasma corticotrophin releasing hormone, vasopressin, ACTH and cortisol responses to acute myocardial infarction [Text] / R. A. Donald [et al.] // Clin. Endocrinol. - 1994. - Vol. 40, N 4. - P499-504 . - ISSN 0300-0664
Перевод заглавия: Содержание в плазме кортиколиберина, вазопрессина, АКТГ и кортизола при остром инфаркте миокарда
Аннотация: We assessed the magnitude and duration of the response of hypothalamic-pituitary-adrenal hormones to the stress of myocardial infarction, in the presence and absence of angiotensin converting enzyme inhibitors. In particular, we wished to analyse the interrelationships between peripheral plasma levels of corticotrophin releasing hormone (CRH), vasopressin (AVP) and adrenocorticotrophin (ACTH), and also between ACTH and cortisol, during a prolonged medical stress. Group 1 (10 patients) received placebo treatment, Group 2 (13 patients) received a maintenance dose of captopril 25 mg three times daily, Group 3 (11 patients) received enalapril 5 mg three times daily. Peptide hormones were measured by radioimmunoassay, and cortisol by ELISA. Reference ranges for all hormones were obtained from 40 or more volunteers from the electoral rotl. Within 6 hours of a myocardial infarction, mean plasma CRH, AVP and cortisol values were very significantly raised above mean control values, while ACTH was very significantly reduced. During the 3 days following an acute myocardial infarction, plasma CRH, AVP and cortisol fell substantially, and this pattern was not influenced by angiotensin converting enzyme inhibitors. By contrast, plasma ACTH showed a significant increase with time. This suggests that the usual relationships between CRH, AVP and ACTH, and between ACTH and corlisol are disturbed in patients admitted to hospital with myocardial infartion. Maximum levels of AVP observed in 12 patients exceeded 60 pmol/l, which may be sufficiently high to interfere with tissue perfusion. It is postulated that V[1] AVP receptor antagonists may have a therapeutic application in limiting infarct size

ГРНТИ	76.31.29

ВИНИТИ 761.31.29.11.11.11
Рубрики: ИНФАРКТЫ МИОКАРДА
ОСТРЫЙ
КАПТОПРИЛ
ЭНАЛАПРИЛ
ДОЗЫ
ПЕПТИДНЫЕ ГОРМОНЫ
СОДЕРЖАНИЕ В ПЛАЗМЕ
ТЕРАПЕВТИЧЕСКИЙ ЭФФЕКТ
БОЛЬНЫЕ

Доп.точки доступа:
Donald, R.A.; Crozier, I.G.; Foy, S.G.; Richards, A.M.; Livesey, J.H.; Ellis, M.J.; Mattioli, L.; Ikram, H.

19.

РЖ ВИНИТИ 76 (BI31) 95.10-04Т3.101

Friart, A.
Le traitement medical de l'insuffisance coronaire du sujet age [Text] / A. Friart // Rev. med. Bruxelles. - 1994. - Vol. 15, N 3. - P99-101
Перевод заглавия: Лекарственное лечение стенокардии в пожилом возрасте
Аннотация: Age does not modify the logical approach of the medical treatment of angina pectoris. Triggering factors have to be searched and treated. Age is not a contra-indication, but the physician has to be familiar with the drugs used in the elderly (side-effects, contra-indications, metabolism, dosages, etc.). The choice based on side-effects and contra-indications favours calcium inhibitors and nitrates. Nevertheless, 'бета'-blocking agents give good results in the elderly, if care is taken to use them correctly. Aspirin{R} is given at reduced dosage. Sublingual nitrates are necessary for the anginal crisis of before stress (prophylaxis). Compliance and safety are favoured by a rational therapy

ГРНТИ	76.31.29

ВИНИТИ 761.31.29.11.11.25
Рубрики: СТЕНОКАРДИЯ
БЛОКАТОРЫ * 'БЕТА'-
АСПИРИН
НИТРАТЫ
СУБЛИНГВАЛЬНОЕ ПРИМЕНЕНИЕ
ТЕРАПЕВТИЧЕСКИЙ ЭФФЕКТ
БОЛЬНЫЕ ПОЖИЛЫЕ

20.

РЖ ВИНИТИ 76 (BI31) 95.10-04Т3.111

Kecskes, A.
Pharmacological activity and local and systemic tolerance of topically applied iloprost [Text] / A. Kecskes, E. Blitstein-Willinger // Arzneim.-Forsch. - 1993. - Vol. 43, N 4. - P450-454 . - ISSN 0004-4172
Перевод заглавия: Фармакологическая активность, локальная и соматическая переносимость местно примененного илопроста
Аннотация: The chemically stable prostacyclin derivative iloprost (CAS 73873-87-7) infused intravenously induces vasodilation and inhibits platelet aggregation. Numerous clinical studies have shown that iloprost is beneficial in the treatment of obliterative arterial disease. As a topical therapy would have considerable advantages, the pharmacological activity and the tolerance of the drug was evaluated in several studies which included 73 healthy volunteers. The drug was tested in different galenical formulations: aqueous solution, various hydrogels and a fatty ointment. They were applied to intact as well as experimentally damaged (stripped) skin. The pharmacodynamic effects were determined by visual assessment, colorimetry and laser Doppler velocimetry. Moreover, the volunteers were monitored for systemic side effects including changes in blood and urine. After the solution was applied under occlusion, iloprost induced erythema at dose levels of at least 50/25 ng/cm{2} (intact/stripped skin). Applied to intact skin, erythema lasted for up to 5 days. When the drug was applied to stripped skin the effect was shorter (24 h). Following low doses, erythema was confined predominantly to the follicles whereas homogeneous redness was induced by higher iloprost doses. Thus penetration seems to occur in particular via the follicles with the horny layer acting as a penetration barrier and as a drug reservoir. High doses (400/150 ng/cm{2}) induced edema in all cases when applied to intactlstripped skin). When applied to large areas of the skin, increased iloprost serum levels ('

ГРНТИ	76.31.29

ВИНИТИ 761.31.29.11.37.11
Рубрики: ОБЛИТЕРИРУЮЩИЙ АРТЕРИИТ
ИЛОПРОСТ
РАЗНЫЕ ЛЕКАРСТВЕННЫЕ ФОРМЫ
МЕСТНОЕ ПРИМЕНЕНИЕ
ДОЗЫ
СРАВНИТЕЛЬНЫЙ АНАЛИЗ
ТЕРАПЕВТИЧЕСКИЙ ЭФФЕКТ
ПОБОЧНЫЕ ЭФФЕКТЫ
ЗДОРОВЫЕ ИСПЫТУЕМЫЕ

Доп.точки доступа:
Blitstein-Willinger, E.

1-20 21-40 41-60 61-80 81-100 101-120

"Электронные каталоги и базы данных библиотек СО РАН"

© Международная Ассоциация пользователей и разработчиков электронных библиотек и новых информационных технологий
(Ассоциация ЭБНИТ)

rtvarBDview(" результаты поиска","20190607010228","4682442");

Вид поиска